medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2013, Number 3

<< Back Next >>

Rev Invest Clin 2013; 65 (3)

Risk factors for the development of thrombotic complication in patients with lupus erythematosus and lupus nephropatic

Zaldívar-Alcántara H, Herrera-Jiménez LE, Dehesa-López E,Correa-Rotter R

Language: Spanish
References: 31
Page: 199-208
PDF size: 162.00 Kb.


ABSTRACT

Introduction. Thrombotic events constitute a frequent complication in patients with systemic lupus erythematosus (SLE) and are associated with increased morbidity and mortality of these patients. Objective. To identify clinical and laboratorial factors associated with the development of arterial or venous thrombosis in patients with SLE and lupus nephritis (LN). Material and methods. We reviewed 200 files of patients with SLE and LN to determine if any patients had presented a symptomatic episode of thrombosis confirmed by an image study. We collected demographic, clinical and laboratory data. Logistic regression was used to determine clinical and laboratorial factors associated with thrombotic complications. Results. There were 25 thrombotic events in 23 patients, of which 68% (n = 17) occurred in the venous bed. The overall incidence rate of thrombotic events was 29.1 per 1,000 patient-years. The class IV was the most frequent class of LN with 40.8% of cases. There were no differences in the distribution of the different classes of NL, eGFR, magnitude of proteinuria and markers of lupus activity among patients with and without thrombotic complications. In multivariate analysis, previous diagnosis of antiphospholipid-antibody syndrome (APS) (OR = 126; IC95% 11.3-1419; p ‹ 0.001), serositis (OR = 5; IC95% 0.95-26.9; p = 0.05) and history of arterial thrombosis (OR = 24; IC95% 1.8-314; p = 0.01) were associated with thrombotic complications and the use of ACE inhibitors showed a protective effect (RM = 0.19; IC95% 0.03-0, 98; p = 0.04). Conclusions. Thrombotic complications were frequent in our population. Risk factors related with thrombotic complications were a personal history of arterial thrombosis, serositis and previous diagnosis of APS. Interestingly, the use of ACE inhibitors was associated with reduced risk. We found no greater or lesser risk of thrombosis with renal factors such as proteinuria, histological type of LN and eGFR.


REFERENCES

  1. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opinion Rheumatol 2001; 13(5): 345-51.

  2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine Baltimore 2003; 83: 299-308.

  3. Gustafsson J, Gunnarsson I, Börjesson O, Petterson S, Möller S, Guo-Zhong F, Elvin K, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus-a prospective cohort study. Arthritis Res Ther 2009; 11: 186.

  4. Toloza SM, Uribe AG, McGwin G Jr, Alarcón GS, Fessler BJ, Bastian HM, et al., for the LUMINA Study Group: Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947-57.

  5. Romero-Díaz J, García-Sosa I, Sánchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2009; 36(2): 1-8.

  6. Kaiser R, Cleveland AM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis Feb 2009; 68: 238-41.

  7. Calvo-Alen J, Toloza SMA, Fernandez M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005; 52: 2060-08.

  8. Tan EM, Cohen As, Fries JF, et al. The 1982 American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.

  9. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.

  10. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52(9): 2774-82.

  11. Chang ER, Pineau CA, Bernatsky S, et al. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. J Rheumatol 2006; 33: 1780-4.

  12. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15.

  13. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-9.

  14. Choojitarom K, Verasertniyom O, Totemchokchyakarn K, et al. Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol 2008; 27(3): 345-51.

  15. Mercadal L, du Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002; 17: 1771–8.

  16. Pasquali S, Banfi G, Zucchelli A, et al. Lupus membranous nephropathy: longterm outcome. Clin Nephrol 1993; 39: 175-82.

  17. Mok CC, Tong KH, To CH, et al., Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis. A comparative study. Medicine 2007; 86(4): 203-09.

  18. Sisó A, Ramos-Casald M, Bové A, et al. Previous antimalarian therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008; 17: 281-8.

  19. Sun HO, Hu WX, Xie HL, et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus 2008; 17: 56-61.

  20. Tarr T, Lakos G, Bhattoa HP, Soltesz P, Shoenfeld Y, Szegedi G, Kiss E. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year followup. Clin Rev Allergy Immunol 2007; 32(2): 131-7.

  21. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16(1): 39-45.

  22. Tektonidou MG, Laskari K, Panagiotakos DB. Risk factors for thrombosis and primary thrombosis prevention in patients with SLE with and without antiphospholipid antibodies. Arthritis Rheum 2009; 61(1): 29-36.

  23. Danowski A, Leitao de Azevedo MN, et al., Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus. J Rheumatol June 2009; 36(6): 1195-9.

  24. Vayá A, Santaolaria M, Micó L, et al. Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects. Clin Hemor Microcirc 2008; 40: 79-97.

  25. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.

  26. De Laat HB, Derksen RH, Urbanus RT, et al. Beta2 glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598-602.

  27. De Laat B, Derksen RH, Urbanus RT, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-5.

  28. Remková A, Remko M. The role of rennin-angiotensin system in prothrombotic state in essential hypertension. Physiol Res 2009; 27.

  29. Remková A, Kratochvíl’ová H, Durina J. Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens 2008; 22(5): 338-45.

  30. Erkan D, Lockshin MD. New treatments for antiphospholipid syndrome. Rheum Dis Clin North Am 2006; 32: 129-48.

  31. Durán-Barragán S, McGwin G Jr, Vilá LM, Reveille JD, Alarcón GS; LUMINA (LIX): a multiethnic US cohort. Angiotensin- converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) 2008; 47(7): 1093-06.




2020     |     www.medigraphic.com